ReGelTec
Manufacturing · Maryland, United States · 1-10 Employees
View Company Info for Free
Overview
Headquarters
323 W Camden St Ste 600, Baltimore, Mary...Phone Number
(443) 451-3915Website
www.regeltec.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
2
1
1
1
1
About ReGelTec
ReGelTec, Inc. is a clinical stage medical device company focused on developing HYDRAFIL, a next-generation injectable hydrogel treatment for chronic low back pain caused by degenerative disc disease. The proprietary hydrogel technology allows for a minimally invasive procedure that integrates with the existing intervertebral disc, preserving spinal motion and significantly reducing pain and disability. The company targets healthcare providers and patients suffering from degenerative disc disease, aiming to improve their quality of life through innovative spinal implants. ReGelTec has received recognition as a breakthrough Medtech startup and has achieved CE Mark approval for its HYDRAFIL System.Explore more
ReGelTec Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is ReGelTec your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Funding: Get notified immidiatlly once ReGelTec has new funding data
Check if ReGelTec has recently received funding, and reach out quickly before it becomes old news!
Earning: See what the market has to say on ReGelTec recently announced quarterly report
Congratulate Masked Content for being promoted to Masked Content at ReGelTec
Click to see if ReGelTec had a recent Job posting/layoffs
Website visits: Recent activity has been detected on your website
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check out if ReGelTec is spiking on competitors!
Product Launch: Get notified when ReGelTec launches new products
ReGelTec, which may be a good buyer, showed buying intent in Masked Content Topic
Recommended Actions
Reach out to Masked Content who joined ReGelTec as Masked Content
Find 3 more new buyers
Compare Similar Companies to ReGelTec
Compare insights from companies similar to ReGelTec, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
ReGelTec is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
ReGelTec is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about ReGelTec.
ReGelTec financials insights
Gather financial insights about ReGelTec, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2020
Series A
$3.8M
ReGelTec Tech Stack
A closer look at the technologies used by ReGelTec
See more technologies
Most Recent Scoops
Project
Laboratory Operations, Medical Research, Clinical Operations
Project
Commentary
Person-Based
Stake & Stock Ownership, Finance
Project
Commentary
Person-Based
Product Development, Product Management, Search, Certifications, Governmental Affairs & Regulation, Medical Research, Clinical Operations, Healthcare Operations, Operations, Regulations
Funding
Funding
ReGelTec News & Media
HYDRAFIL® Presentation Receives Top Abstract Award at the 6th Annual American Society of Pain and Neuroscience Annual Meeting
BALTIMORE--(BUSINESS WIRE)--ReGelTec, Inc., announced that Dr. Douglas Beall received the “Top Abstract Award” from the American Society of Pain and Neuroscience (ASPN) for his presentation of the 3-Year follow-up data on chronic low back pain patients treated with ReGelTec’s HYDRAFIL System. The presentation was given to a packed room of physicians at the 6th Annual meeting of ASPN in Miami, Florida. The HYDRAFIL System allows doctors to treat chronic low back pain due to degenerativeThe FDA Approves IDE for ReGelTec’s Pivotal Study of HYDRAFIL® for Chronic Low Back Pain due to Degenerative Disc Disease
BALTIMORE--(BUSINESS WIRE)--ReGelTec, Inc., announced that the U.S. Food and Drug Administration has approved an IDE for the company’s pivotal study to support premarket approval of its HYDRAFIL® System. The HYDRAFIL System contains an injectable polymer that is implanted percutaneously via a needle to augment the native disc in a procedure performed under local anesthesia at an outpatient surgery center. The HYDRogel Augmentation For Intervertebral Lumbar Discs (HYDRAFIL-D) Study, is a multiceBCWorld Healthcare and ReGelTec have entered into an exclusive distribution agreement for HYDRAFIL™ in the South Korean market
BALTIMORE--(BUSINESS WIRE)--ReGelTec, Inc. (ReGelTec) announced that it has entered into an agreement with BCWorld Healthcare Co., Ltd. (BCWH) that provides BCWP exclusive rights to distribute the HYDRAFIL™ System for the treatment of Chronic Low Back Pain (CLBP) due to Degenerative Disc Disease (DDD) in the South Korean market. The agreement includes an investment by BCWH in ReGelTec. BCWH will also fund a clinical study in South Korea to support regulatory approval from the Ministry ofInventor of High Flow Nasal Cannula, Veteran Medical Industry Executive Join MedTech Startup Board of Directors
Bill Niland and Matt Vogelhuber to help guide fluidIQ's next phase of growth LOS ANGELES, CA, USA, August 11, 2021 /EINPresswire.com/ -- fluidIQ, a startup MedTech company launched by a team of emergency and respiratory doctors, patient advocates …
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding ReGelTec
Sign Up For FreeTo access detailed company insights
ReGelTec, Inc. is a clinical stage medical device company focused on developing HYDRAFIL, a next-generation injectable hydrogel treatment for chronic low back pain caused by degenerative disc disease. The proprietary hydrogel technology allows for a minimally invasive procedure that integrates with the existing intervertebral disc, preserving spina... Read More
